June 2025 in “Frontiers in Bioengineering and Biotechnology” Recombinant collagen with nicotinamide boosts hair growth and health.
January 2026 in “RSC Medicinal Chemistry” 2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
6 citations
,
February 2016 in “Journal of Microencapsulation” Improved finasteride formula allows slow, sustained release and better absorption for patients.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
123 citations
,
May 2009 in “Journal of Neuroscience” In late pregnancy, allopregnanolone reduces stress responses in rats by affecting brain chemicals.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
62 citations
,
January 2009 in “Biochemistry” Vitamin D receptor binds similarly to natural and synthetic ligands, affecting gene regulation.
January 2021 in “Social Science Research Network” The optimized microemulsion with finasteride and cinnamon oil can effectively deliver the drug through the skin without using ethanol.
June 2024 in “Pharmacon Jurnal Farmasi Indonesia” A 1:3 ratio of virgin coconut oil to candlenut oil is best for promoting hair growth.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
271 citations
,
September 2008 in “Nutrition reviews” Vitamin D receptor interacts with certain dietary components to help prevent diseases and regulate hair growth.
1 citations
,
December 2025 in “Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)” Spanlastics effectively deliver Rizatriptan Benzoate with high efficiency and controlled release.
6 citations
,
May 2023 in “Molecules” Cepharanthine dry powder inhalers may effectively treat acute lung injury by reducing inflammation.
1 citations
,
November 2025 in “Journal of Cosmetic Dermatology” CBD might help with skin issues, but more research is needed.
5 citations
,
January 2000 in “Inhalation Toxicology” Aqueous dispersion resin is safe to inhale at levels below 30 mg/m³.
18 citations
,
September 1979 in “DMW - Deutsche Medizinische Wochenschrift” Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
164 citations
,
January 2003 in “Drugs”
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
21 citations
,
March 2002 in “Neurology” Dopamine agonists like pramipexole and ropinirole can cause reversible hair loss.
February 2020 in “Definitions” Botanical lotion CG428 may help regrow hair and reduce scalp inflammation in chemotherapy patients.
33 citations
,
November 2020 in “AAPS PharmSciTech” February 2026 in “JAAD International” June 2026 in “Frontiers in Nutrition” The document discusses the use of GLP-1 receptor agonists (GLP-1RAs) in managing Polycystic Ovary Syndrome (PCOS), focusing on their metabolic benefits rather than confirmed fertility enhancement. The narrative synthesis highlights the need for individualized treatment plans, emphasizing the distinction between metabolic optimization and reproductive outcomes. The study suggests GLP-1RAs should be used as short-term, preconception tools, with careful planning for drug discontinuation to avoid rebound effects. The authors call for future trials to standardize reproductive endpoints and capture periconception exposure to better assess the benefits and risks.